Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Blood (2023) 141 (19): 2307–2315.

https://doi.org/10.1182/blood.2022018893

Published: 2023

Includes: Supplemental data

Journal Articles

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Blood (2022) 140 (Supplement 1): 3158–3161.

https://doi.org/10.1182/blood-2022-158248

Published: 2022

Journal Articles

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Blood (2022) 140 (Supplement 1): 8019–8021.

https://doi.org/10.1182/blood-2022-167411

Published: 2022

Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Blood (2022) 140 (Supplement 1): 9057–9060.

https://doi.org/10.1182/blood-2022-169307

Published: 2022

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Blood (2022) 140 (Supplement 1): 10399–10401.

https://doi.org/10.1182/blood-2022-156117

Published: 2022

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Susan Prockop, Kris Michael Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi

Blood (2021) 138 (Supplement 1): 301.

https://doi.org/10.1182/blood-2021-147274

Published: 2021

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Blood (2021) 138 (Supplement 1): 2832.

https://doi.org/10.1182/blood-2021-147403

Published: 2021

Journal Articles

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

Blood (2021) 138 (Supplement 1): 1791.

https://doi.org/10.1182/blood-2021-148497

Published: 2021

Journal Articles

CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial

Sikander Ailawadhi, Patrick Stiff, Emad Ibrahim, Damian J. Green, Brea Lipe, Elizabeth H. Cull, Natalie S. Callander, John Friend, Jarrod Longcor, Kate Oliver

Blood (2021) 138 (Supplement 1): 1652.

https://doi.org/10.1182/blood-2021-152682

Published: 2021

Journal Articles

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Blood (2021) 138 (Supplement 1): 1764.

https://doi.org/10.1182/blood-2021-148078

Published: 2021

Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Blood (2018) 132 (25): 2639–2642.

https://doi.org/10.1182/blood-2018-07-861641

Published: 2018

Journal Articles

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, MDPhDProf, Auayporn P. Nademanee, MD, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, MD, Andy I Chen, MD PhD, Patrick Stiff, Simonetta Viviani, MD, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanova, MD, Anna Sureda, MD PhD, Dirk Huebner, Emily K Larsen, Naomi N Hunder, Craig H Moskowitz, MD

Blood (2015) 126 (23): 3172.

https://doi.org/10.1182/blood.V126.23.3172.3172

Published: 2015

Journal Articles

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Jennifer A. Kanakry, Hailun Li, Lan L. Gellert, M. Victor Lemas, Wen-son Hsieh, Fangxin Hong, King L. Tan, Randy D. Gascoyne, Leo I. Gordon, Richard I. Fisher, Nancy L. Bartlett, Patrick Stiff, Bruce D. Cheson, Ranjana Advani, Thomas P. Miller, Brad S. Kahl, Sandra J. Horning, Richard F. Ambinder

Blood (2013) 121 (18): 3547–3553.

https://doi.org/10.1182/blood-2012-09-454694

Published: 2013

Includes: Supplemental data

Journal Articles

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

Urszula A Sobol, MD, Tulio E. Rodriguez, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Ross Vimr, MD, Mala Parthasarathy, MS, Rong Guo, MS, Patrick Stiff, MD

Blood (2012) 120 (21): 3131.

https://doi.org/10.1182/blood.V120.21.3131.3131

Published: 2012

Journal Articles

Cardiac Complications Following Allogeneic Bone Marrow Transplantation: Evaluation of Risk Factors, Outcomes and Enhanced Screening for At Risk Populations.

Michael Henry, BS, Rong Guo, MS, Mala Parthasarathy, MS, John Lopez, MD, Patrick Stiff, MD

Blood (2012) 120 (21): 3070.

https://doi.org/10.1182/blood.V120.21.3070.3070

Published: 2012

Journal Articles

Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

Brian Hess, MD, Matthew Siegel, MD, Tulio E. Rodriguez, MD, Shams Bakhos, MD, Maria Theodorou, Michael Tallarico, MD, Scott E. Smith, MD, PhD, Aileen Go, MD, Patrick Stiff, MD

Blood (2012) 120 (21): 3102.

https://doi.org/10.1182/blood.V120.21.3102.3102

Published: 2012

Journal Articles

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

James R. Cook, MD, PhD, Bryan H. Goldman, MS, Raymond R. Tubbs, DO, Michael LeBlanc, PhD, Lisa M. Rimsza, MD, Patrick Stiff, MD, Richard I Fisher, MD

Blood (2012) 120 (21): 543.

https://doi.org/10.1182/blood.V120.21.543.543

Published: 2012

Journal Articles

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

Ranjana Advani, MD, Fangxin Hong, PhD, Leo I. Gordon, MD, FACP, Randy D. Gascoyne, MD, Henry Wagner, MD, Richard T. Hoppe, MD, Richard I Fisher, MD, Nancy L. Bartlett, MD, Brad S. Kahl, MD, Patrick Stiff, MD, Bruce D. Cheson, MD, Andrew R Belch, MD, Jonathan W. Friedberg, MD, MMSc, Jeannine Kassis, MD, Kristie A. Blum, MD, Thomas M. Habermann, MD, Joseph Tuscano, MD, Sandra J. Horning, MD

Blood (2011) 118 (21): 1603.

https://doi.org/10.1182/blood.V118.21.1603.1603

Published: 2011

NARROW

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6)

Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies

CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial

Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.

Cardiac Complications Following Allogeneic Bone Marrow Transplantation: Evaluation of Risk Factors, Outcomes and Enhanced Screening for At Risk Populations.

Correlation of Ethnicity, Socioeconomic Status, and Co-Morbidity with Outcome After Allogeneic Hematopoietic Stem Cell Transplantation.

MYC Protein Expression, but Not High Grade Morphology, Is Associated with Poor Outcome in Non-Burkitt Diffuse Aggressive B-Cell Lymphomas: A SWOG S9704 Correlative Study

Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only